CorMedix Inc
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Pict… Read more
CorMedix Inc (CRMD) - Total Liabilities
Latest total liabilities as of September 2025: $376.73 Million USD
Based on the latest financial reports, CorMedix Inc (CRMD) has total liabilities worth $376.73 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
CorMedix Inc - Total Liabilities Trend (2008–2024)
This chart illustrates how CorMedix Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
CorMedix Inc Competitors by Total Liabilities
The table below lists competitors of CorMedix Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Global Medical REIT Inc.
NYSE:GMRE
|
USA | $767.41 Million |
|
Beijing Bayi Space LCD Technology Co Ltd
SHG:688181
|
China | CN¥1.10 Billion |
|
Time Technoplast Limited
NSE:TIMETECHNO
|
India | ₹14.00 Billion |
|
Guanhao Biotech Co Ltd
SHE:300238
|
China | CN¥281.01 Million |
|
Guangzhou Guangri Stock Co Ltd
SHG:600894
|
China | CN¥5.75 Billion |
|
i3 Verticals Inc
NASDAQ:IIIV
|
USA | $112.59 Million |
|
Flaircomm Microelectronics Inc Ordinary Shares - Class A
SHE:301600
|
China | CN¥360.49 Million |
|
Greenvolt Energias Renovaveis SA
LS:GVOLT
|
Portugal | €1.92 Billion |
Liability Composition Analysis (2008–2024)
This chart breaks down CorMedix Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.94 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.01 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.50 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how CorMedix Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for CorMedix Inc (2008–2024)
The table below shows the annual total liabilities of CorMedix Inc from 2008 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $34.19 Million | +186.88% |
| 2023-12-31 | $11.92 Million | +70.77% |
| 2022-12-31 | $6.98 Million | +13.52% |
| 2021-12-31 | $6.15 Million | +20.89% |
| 2020-12-31 | $5.09 Million | -12.77% |
| 2019-12-31 | $5.83 Million | -58.03% |
| 2018-12-31 | $13.89 Million | +121.89% |
| 2017-12-31 | $6.26 Million | +53.00% |
| 2016-12-31 | $4.09 Million | +32.41% |
| 2015-12-31 | $3.09 Million | +111.18% |
| 2014-12-31 | $1.46 Million | -79.07% |
| 2013-12-31 | $6.99 Million | +329.20% |
| 2012-12-31 | $1.63 Million | +23.43% |
| 2011-12-31 | $1.32 Million | -17.14% |
| 2010-12-31 | $1.59 Million | -90.60% |
| 2009-12-31 | $16.93 Million | +24.09% |
| 2008-12-31 | $13.65 Million | -- |